Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

Bristol-Myers Squibb Company. (3/18/20). "Press Release: Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development". New York, NY.

Organisations Organisation Bristol-Myers Squibb Co. (BMS) (NYSE: BMY)
  Group Bristol-Myers Squibb (BMS) (Group)
  Organisation 2 Barclays (Group)
Products Product pharmaceutical
  Product 2 investment banking
Persons Person Mily, Elizabeth (BMS 202003– EVP Strategy + Business Development before Barclays + Thermo Fisher + Goldman Sachs)
  Person 2 Caforio, Giovanni (BMS 201606 CEO)
     


Bristol Myers Squibb Company (NYSE:BMY) announced today that Elizabeth Mily has been appointed Executive Vice President, Strategy & Business Development, effective March 30, 2020. In this role, Mily will oversee company strategy and all business development activities, including strategic partnerships, mergers and acquisitions, as well as other strategic initiatives.

“Elizabeth is an accomplished leader in investment banking and health care M&A, and I look forward to the important role she will play in sourcing external innovation to drive our vision of transforming patients’ lives through science,” said Giovanni Caforio, chairman and chief executive officer, Bristol Myers Squibb. “I am excited to welcome her to Bristol Myers Squibb as we position the company for continued growth through high performing brands, upcoming new product launches, an exciting pipeline, and the financial strength to pursue innovation for the next wave of new medicines.”

Mily will report to Caforio and will be a member of the Bristol Myers Squibb leadership team.

Mily joins Bristol Myers Squibb from Barclays, where she was the Managing Director and Chair of the Global Lifesciences group in the global healthcare unit. During her career she has executed over $200 billion in completed M&A advisory assignments and has advised on an extensive amount of debt, equity and equity-linked financings. Prior to joining Barclays, Mily served as Head of Corporate Strategy and Development at Thermo Fisher Scientific. Prior to that she spent 16 years at Goldman, Sachs & Co. where she was a Managing Director and senior coverage officer within the Healthcare Department of the Investment Banking Division.


About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.


Contact:

Media:
media@bms.com
609-252-3345

Investors:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, ngoworek@bms.com

   
Record changed: 2020-03-20

Advertisement

Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 650x65px

More documents for Bristol-Myers Squibb (BMS) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top